Ultragenyx director Aliski to exit at 2022 annual meeting; appoints Amrit Ray to board

Ultragenyx Pharmaceutical Inc.

William Aliski will not stand for re-election at 2022 annual meeting; departure for personal reasons, not disagreement.
Amrit Ray, M.D., appointed as Class III director effective April 19, 2022; also joins Research and Development Committee.
Ray is Chief Patient Officer at Biohaven (BHVN); previously senior roles at Pfizer and Johnson & Johnson.
Ray granted 5,120 RSUs and option for 9,525 shares at $78.10 exercise price under standard director compensation.
Board size set at ten directors: three Class I, three Class II, four Class III.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

William Aliski

director

RARE · Ultragenyx Pharmaceutical Inc.

Filed: April 22, 2022, 7:59 PM ET

William Aliski notified Ultragenyx Pharmaceutical Inc. (the “ Company ”) that he will not stand for re-election as a member of the Board of Directors

Appointed

Amrit Ray

Class III director

RARE · Ultragenyx Pharmaceutical Inc.

Effective: 2022-04-19
Filed: April 22, 2022, 7:59 PM ET

the Board appointed Amrit Ray, M.D. as a Class III director of the Board effective April 19, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William Aliski departed as director at Ultragenyx Pharmaceutical Inc..

Action: not stand for re-election
Role: director

Exact text from the filing

William Aliski notified Ultragenyx Pharmaceutical Inc. (the “ Company ”) that he will not stand for re-election as a member of the Board of Directors

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Amrit Ray was appointed as Class III director at Ultragenyx Pharmaceutical Inc..

Action: appointed
Role: Class III director

Exact text from the filing

the Board appointed Amrit Ray, M.D. as a Class III director of the Board effective April 19, 2022

View on SEC.gov

Ultragenyx Pharmaceutical Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-005981

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.